Two Cases of Amivantamab-Induced Pneumonitis in Patients With NSCLC: Case Report
Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced interstitial lung disease in patients with canonical EGFR mutant NSCLC after progression on osimertinib.
Authors
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Alexander J. DeWeerd
- Elizabeth Sun (ORCID: https://orcid.org/0000-0001-6612-1313)
Institutions
- Vanderbilt University (US)
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100805
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Vanderbilt University
- National Comprehensive Cancer Network